Bristol-Myers Squibb: In phase 3 breast cancer studies, isabemumab reduced the risk of disease progression or death by 59%.

Bristol-Myers Squibb: In phase 3 breast cancer studies, isabemumab reduced the risk of disease progression or death by 59%.